Leeman JE, Li JG, Pei X, et al. Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation techniques. JAMA Oncol 2017;3(11):1487-94.
DOI: 10.1001/jamaoncol.2017.0973
Muzaffar J, Bari S, Kirtane K, et al. Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. Cancers 2021;13(2):338.
DOI: 10.3390/cancers13020338
Machiels JP, René Leemans C, Golusinski W. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31(11):1462-75.
DOI: 10.1016/j.annonc.2020.07.011
Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515:568-71.
DOI: 10.1038/nature13954
Huang Z, Zheng S, Ding S, et al. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials. J Cancer Res Ther 2021;17:676-87.
DOI: 10.4103/jcrt.JCRT_1606_20
Emancipator K, Huang L, Aurora-Garg D, et al. Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Mod Pathol 2021;34:532-41.
DOI: 10.1038/s41379-020-00710-9
Zhang Y, Lin A, Li Y, et al. Age and mutations as predictors of the response to immunotherapy in head and neck squamous cell cancer. Front Cell Dev Biol 2020;8:608969.
DOI: 10.3389/fcell.2020.608969
Haddad RI, Seiwert TY, Chow LQM, et al. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Cancer 2022;10:e003026.
DOI: 10.1136/jitc-2021-003026
Yilmaz E, Ismaila N, Bauman JE, et al. Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline. J Clin Oncol 2023;41(5):1132-46.
DOI: 10.1200/JCO.22.02328
Mena M, Frias-Gómez J, Taberna M, et al. Epidemiology of human papillomavirus-related oropharyngeal cancer in a classically low-burden region of southern Europe. Sci Rep 2020;10(1):13219.
DOI: 10.1038/s41598-020-70118-7
Menezes FDS, Fernandes GA, Antunes JLF, et al. Global incidence trends in head and neck cancer for HPV-related and -unrelated subsites: A systematic review of population-based studies. Oral Oncol 2021;115:105177.
DOI: 10.1016/j.oraloncology.2020.105177
NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers, Version 1.2024.
Lewis JS, Beadle B, Bishop JA. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline from the College of American Pathologists. Arch Pathol Lab Med 2018;142(5):559-97.
DOI: 10.5858/arpa.2017-0286-CP
Prigge ES, Arbyn M, von Knebel Doeberitz M, et al. Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis. Int J Cancer 2017;140(5):1186-98.
DOI: 10.1002/ijc.30516
Taberna M, Mena M, Pavón MA, et al. Human papillomavirus-related oropharyngeal cancer. Ann Oncol 2017;28(10):2386-98.
DOI: 10.1093/annonc/mdx304
Vermorken JB, Psyrri A, Mesía R, et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol 2014;25(4):801-7.
DOI: 10.1093/annonc/mdt574
Guigay J, Aupérin A, Fayette J, et al. Cetuximab, docetaxel, and cisplatin frente a platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2021;22(4):463-75.
DOI: 10.1016/S1470-2045(20)30755-5
Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy vs. cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet Lond Engl 2019;394(10212):1915-28.
DOI: 10.1016/S0140-6736(19)32591-7
Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 2018;81:45-51.
DOI: 10.1016/j.oraloncology.2018.04.008
Wang J, Sun H, Zeng Q, et al. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Sci Rep 2019;9:13404.
DOI: 10.1038/s41598-019-49771-0
Burtness B, Rischin D, Greil R, et al. Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death ligand-1 combined positive score. J Clin Oncol 2022;40(21):2321-32.
DOI: 10.1200/JCO.21.02198
Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27.
DOI: 10.1056/NEJMoa0802656
Hitt R, Irigoyen A, Cortes-Funes H, et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 2012;23(4):1016-22.
DOI: 10.1093/annonc/mdr367
Cohen EEW, Soulieres D, Le Tourneau C, et al. KEYNOTE-040 investigators. Pembrolizumab frente a methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393:156-67.
DOI: 10.1016/S0140-6736(18)31999-8
Rubio-Casadevall J, Cirauqui B, Martínez Rufero J, et al. TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck. Front Oncol 2023;13:1226939.
DOI: 10.3389/fonc.2023.1226939
Grau JJ, Caballero M, Verger E. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol 2009;129(11):1294-9.
DOI: 10.3109/00016480802590451
Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer Oxf Engl2004;40(14):2071-6.
DOI: 10.1016/j.ejca.2004.05.019
Martínez-Trufero J, Isla D, Adansa JC, et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer 2010;102(12):1687-91.
DOI: 10.1038/sj.bjc.6605697
Szabados B, van Dijk N, Tang YZ, et al. Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. Eur Urol 2018;73(2):149-52.
DOI: 10.1016/j.eururo.2017.08.022
Park SE, Lee SH, Ahn JS, et al. Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer. J Thor Oncol 2018;13(1).
DOI: 10.1016/j.jtho.2017.10.011
Saleh K, Daste A, Martin N, et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 2019;121.
DOI: 10.1016/j.ejca.2019.08.026
Cabezas-Camarero S, Cabrera-Martín MN, Merino-Menéndez S, et al. Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer. Oncologist 2021;26(6):e1028-36.
DOI: 10.1002/onco.13754
Wakasaki T, Manako T, Yasumatsu R, et al. Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study. PLoS One. 2022;17(7):e0271907.
DOI: 10.1371/journal.pone.0271907
Harrington KJ, Burtness B, Greil R, et al. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clinc Oncol 2023;41(4):790-802.
DOI: 10.1200/JCO.21.02508
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-64.
DOI: 10.1038/nrc3239
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer 2019;19:816.
DOI: 10.1186/s12885-019-5977-6
Tang E, Lahmi L, Meillan N, et al. Treatment strategy for distant synchronous metastatic head and neck squamous cell carcinoma. Curr Oncol Rep 2019;21:102.
DOI: 10.1007/s11912-019-0856-5
Fleming CW, Ward MC, Woody NM, et al. Identifying an oligometastatic phenotype in HPV-associated oropharyngeal squamous cell cancer: Implications for clinical trial design. Oral Oncol 2021;112:105046
DOI: 10.1016/j.oraloncology.2020.105046
Filatenkov A, Baker J, Mueller AM, et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res 2015;21:3727-39.
DOI: 10.1158/1078-0432.CCR-14-2824
McBride S, Sherman E, Tsai CJ, et al. Randomized phase II trial of nivolumab with stereotactic body radiotherapy frente a nivolumab alone in metastatic head and neck squamous cell carcinoma. J Clin Oncol 2021;39:30-7.
DOI: 10.1200/JCO.20.00290
Vincent AG, Wang W, Ducic Y, et al. Treatment of oligometastatic disease in squamous cell carcinoma of the head and neck. Laryngoscope 2021;131:E1476-80.
DOI: 10.1002/lary.29115
Weissman T, Hofler D, Hecht M, et al. Oligometastatic head and neck cancer: which patients benefit from radical local treatment of all tumour sites? Radiat Oncol 2021;16:62.
DOI: 10.1186/s13014-021-01790-w
Franzese C, Badalamenti M, Teriaca A, et al. Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer. J Cancer Res Clin Oncol 2021;147:1307-13.
DOI: 10.1007/s00432-021-03518-5
Pasalic D, Betancourt-Cuellar SL, Taku N, et al. Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head Neck 2020;42:1939-53.
DOI: 10.1002/hed.26117
Bates JE, De Leo AN, Morris CG, et al. Oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy: single-institution outcomes. Head Neck 2019;41:2309-14.
DOI: 10.1002/hed.25695
Bonomo P, Greto D, Desideri I, et al. Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal? Oral Oncol 2019;93:1-7.
DOI: 10.1016/j.oraloncology.2019.04.006
Oki T, Hishida T, Yoshida J, et al. Survival and prognostic factors after pulmonary metastasectomy of head and neck cancer: what are the clinically informative prognostic indicators? Eur J Cardiothorac Surg 2019;55:942-7.
DOI: 10.1093/ejcts/ezy384
Shiono S, Kawamura M, Sato T, et al. Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas. Ann Thorac Surg 2009; 88:856-60.
DOI: 10.1016/j.athoracsur.2009.04.040
Vanbutsele G, Pardon K, Van Belle S, et al. Effect of early and systematic integration of palliative care in patients with advanced cancer: a randomised controlled trial. Lancet Oncol 2018;19(3):394-404.
DOI: 10.1016/S1470-2045(18)30060-3
Fulton JJ, LeBlanc TW, Cutson TM, et al. Integrated outpatient palliative care for patients with advanced cancer: A systematic review and meta-analysis. Palliat Med 2019;33(2):123-34.
DOI: 10.1177/0269216318812633
Balboni TA, Smith TJ, Ferrell BR, et al. Integration of Palliative Care into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017;35(1):96-112.
DOI: 10.1200/JCO.2016.70.1474
Jordan K, Aapro M, Kaasa S, et al. European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Ann Oncol 2018;29(1):36-43.
DOI: 10.1093/annonc/mdx757
Lin C, Kang SY, Donermeyer S, et al. Supportive Care Needs of Patients with Head and Neck Cancer Referred to Palliative Medicine. Otolaryngol - Head Neck Surg U S 2020;163(2):356-63.
DOI: 10.1177/0194599820912029
Bauman JR, Panick JR, Galloway TJ, et al. A Pilot Study of a Collaborative Palliative and Oncology Care Intervention for Patients with Head and Neck Cancer. J Palliat Med 2021;24(11):1673-81.
DOI: 10.1089/jpm.2020.0656
Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr 2021;40(5):2898-913.
DOI: 10.1016/j.clnu.2021.02.005
August DA, Huhmann MB, American Society for Parenteral and Enteral Nutrition (ASPEN) Board of Directors. ASPEN clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr 2009;33(5):472-500.
DOI: 10.1177/0148607109341804
Wildiers H, Heeren P, Puts M. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014;32(24):2595-603.
DOI: 10.1200/JCO.2013.54.8347
Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. Ann Oncol 2015;26(2):288-300.
DOI: 10.1093/annonc/mdu210